Cargando…
Protein and Peptide Nanoparticles for Drug Delivery /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Waltham, MA :
Academic Press,
2015.
|
| Colección: | Advances in protein chemistry and structural biology ;
v. 98. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn906032488 | ||
| 003 | OCoLC | ||
| 005 | 20231120111949.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 150402s2015 mauad o 001 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d YDXCP |d OCLCF |d UAB |d MEU |d D6H |d OCLCQ |d UKBTH |d UKMGB |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 015 | |a GBB515462 |2 bnb | ||
| 016 | 7 | |a 017039434 |2 Uk | |
| 020 | |a 9780128028285 | ||
| 020 | |a 0128028289 | ||
| 020 | |a 9780128028704 |q (PDF ebook) | ||
| 020 | |a 012802870X | ||
| 035 | |a (OCoLC)906032488 | ||
| 050 | 4 | |a RS201.N35 |b .P768 2015eb | |
| 082 | 0 | 4 | |a 615.1/9 |2 23 |
| 245 | 0 | 0 | |a Protein and Peptide Nanoparticles for Drug Delivery / |c edited by Rossen Donev. |
| 264 | 1 | |a Waltham, MA : |b Academic Press, |c 2015. | |
| 300 | |a 1 online resource (386 pages) : |b illustrations, tables | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Advances in protein chemistry and structural biology ; |v volume 98 | |
| 546 | |a Text in English. | ||
| 500 | |a Includes indexes. | ||
| 588 | 0 | |a Online resource; title from title details screen (ScienceDirect, viewed April 2, 2015). | |
| 505 | 0 | |a Front Cover; Protein and Peptide Nanoparticles for Drug Delivery; Copyright; Contents; Contributors; Preface; References; Chapter One: Protein- and Peptide-Drug Conjugates: An Emerging Drug Delivery Technology; 1. Introduction; 2. Protein-Drug Conjugates; 2.1. Albumin-drug conjugates; 2.2. Transferrin-drug conjugates; 2.3. Gelatin-drug conjugates; 2.4. Antibody-drug conjugates; 2.5. Other protein-drug conjugates; 3. Peptide-Drug Conjugates; 3.1. RGD peptide-drug conjugates; 3.2. Cell penetrating peptide-drug conjugates; 4. Strategies for Chemical Conjugation; 4.1. Linker technologies | |
| 505 | 8 | |a 4.1.1. Cleavable linkers4.1.2. Noncleavable linkers; 5. Challenges; 6. Future Perspective; 7. Conclusion; References; Chapter Two: Modifications of Natural Peptides for Nanoparticle and Drug Design; 1. Introduction; 2. Role of Nanoparticles in Peptide Drug Delivery; 3. Cell-Penetrating Peptides; 3.1. Structure and properties; 3.1.1. Cationic CPPs; 3.1.2. Amphipathic CPPs; 3.1.3. Hydrophobic CPPs; 3.2. Applications in nanoparticle delivery; 3.2.1. Tat peptide; 3.2.2. Penetratin; 3.2.3. MPG/Pep-1; 3.2.4. Antimicrobial peptides; 4. Antimicrobial Peptides; 4.1. Sequence modifications | |
| 505 | 8 | |a 4.2. Nanoparticle delivery strategies5. Peptide Toxins; 5.1. Mechanisms of action; 5.2. Therapeutic applications; 5.2.1. Amphibian toxins; 5.2.2. Bee venom; 5.2.3. Scorpion venom; 5.2.4. Snake venom; 6. Conclusion; References; Chapter Three: Hybrid Protein-Synthetic Polymer Nanoparticles for Drug Delivery; 1. Introduction; 2. Nanoparticles Derived from Polymer(s) and Covalently Bound Protein(s); 2.1. Hybrid micelles derived from copolymers of PEG and PGlu; 2.2. Hybrid nanoparticles based on (bio)degradable polyesters; 2.3. Hybrid nanoparticles based on nondegradable polymers | |
| 505 | 8 | |a 3. Hybrid Nanoparticles Based on Electrostatic Interactions Between Proteins/Peptides and Synthetic Polyelectrolytes4. Conclusions; References; Chapter Four: Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles; 1. Introduction; 2. Albumin Nanoparticles' Fabrication Methods; 3. Albumin-Nanoparticles-Targeting Strategies; 4. Albumin Nanoparticles as a Drug Delivery Carrier; 4.1. Chemotherapeutic agents; 4.1.1. Paclitaxel; 4.1.2. Doxorubicin; 4.1.3. Other drugs; 4.2. Biological macromolecules; 5. Albumin Nanoparticles Marketed and Under Clinical Trial; 6. Conclusions | |
| 650 | 0 | |a Nanoparticles. | |
| 650 | 0 | |a Peptide drugs |x Dosage forms. | |
| 650 | 0 | |a Protein drugs |x Dosage forms. | |
| 650 | 2 | |a Nanoparticles |0 (DNLM)D053758 | |
| 650 | 6 | |a Nanoparticules. |0 (CaQQLa)201-0262530 | |
| 650 | 6 | |a M�edicaments peptidiques |x Formes pharmaceutiques. |0 (CaQQLa)201-0263775 | |
| 650 | 6 | |a M�edicaments prot�eiques |x Formes pharmaceutiques. |0 (CaQQLa)201-0263778 | |
| 650 | 7 | |a Nanoparticles |2 fast |0 (OCoLC)fst01032624 | |
| 650 | 7 | |a Peptide drugs |x Dosage forms |2 fast |0 (OCoLC)fst01057557 | |
| 650 | 7 | |a Protein drugs |x Dosage forms |2 fast |0 (OCoLC)fst01079681 | |
| 700 | 1 | |a Donev, Rossen, |e editor. | |
| 776 | 0 | 8 | |i Print version: |z 9780128028285 |
| 830 | 0 | |a Advances in protein chemistry and structural biology ; |v v. 98. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128028285 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/98 |z Texto completo |